Wos İndeksli Açık & Kapalı Erişimli Yayınlar

Permanent URI for this communityhttps://hdl.handle.net/11727/10751

Browse

Filters

2015 - 20162

Settings

Author: search.filters.author.Kervancioglu, EnisSubject: search.filters.subject.Prostate cancer

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Evaluation of the Current Situation Tissue and Serum Biomarkers in Prostate Cancer
    (2015) Kervancioglu, Enis; Kosan, Murat
    Prostate cancer, is the most commonly diagnosed cancer in the United States and in many parts of the world and ranks 2nd in death from cancer among men. Lifetime risk of developing prostate cancer is 16%. Currently the only accepted screening tool Prostate Specific Antigen (PSA) and Digital Rectal Examination (DRE). PSA is a specific biomarker but non-specific for prostate cancer. In diseases such as Benign Prostatic Hyperplasia (BPH) and prostatitis high serum PSA levels can be detected. Therefore, identifying prostate cancer only with serum PSA measurement has lower specificity and may lead to false positive results and unnecessary biopsies. Some encountered problems such as unnecessary diagnoses of clinically insignificant cancer and the non-diagnosis of early stage cancers can take. In recent years there are too many studies to investigate new biomarkers for replacing or helping PSA. The aim of this article was the evaluation of the current situation for PSA and non-PSA tissue and serum biomarkers which are published.
  • Thumbnail Image
    Item
    Predictive values of vascular endothelial growth factor and microvessel-density levels in initial biopsy for prostate cancer
    (2016) Kervancioglu, Enis; Kosan, Murat; Erinanc, Hilal; Gonulalan, Umut; Oguzulgen, Ahmet Ibrahim; Coskun, Esra Zeynep; Ozkardes, Hakan; 26944325
    Angiogenesis is an important factor in the development and progression of prostate cancer (PCA). We aimed to investigate the values of vascular-endothelial-growth-factor (VEGF) expression level and microvessel density (MVD) in the prediction of PCA diagnosis at repeated prostate biopsy (re-PBx). We retrospectively evaluated 167 patients with re-PBx according to elevated prostate-specific antigen levels, suspicious digital rectal examination, and the presence of premalignant lesions. Patients with PCA on re-PBx were included in the cancer group (n = 17). Patients with benign prostatic hyperplasia or normal tissues on re-PBx were included in the control group (n = 21). The groups were compared according to the expression level of VEGF and MVD in initial prostate biopsy. There was no statistically significant difference between groups according to age and serum prostate-specific-antigen values. The mean VEGF scores of the cancer and control groups were 232.64 +/- 11.14 and 183.09 +/- 14.56, respectively (p < 0.05). The mean MVD of the biopsy samples in the cancer and control groups were 246.47 +/- 17.59 n/mm(2) and 197.33 +/- 16.26 n/mm(2), respectively (p < 0.05). The cutoff values of VEGF scores and MVD were set as 200 and 215, respectively, for PCA detection in our study. Our results showed that the expression level of VEGF and MVD significantly increased in the initial prostate-biopsy samples of patients with PCA diagnosed with re-PBx. The evaluation of VEGF expression level and MVD might have an important value in the prediction of PCA at re-PBx. The expression level of VEGF and MVD should be kept in mind as PCA-related histopathological changes that indicate the increased angiogenesis in prostatic tissue. Copyright (C) 2015, Kaohsiung Medical University. Published by Elsevier Taiwan LLC.